Literature DB >> 23722323

Interleukin-12p40 in the spinal fluid as a biomarker for clinically isolated syndrome.

Rotem Orbach1, Michael Gurevich, Anat Achiron.   

Abstract

BACKGROUND: The cerebrospinal (CSF) constitutes a specific immune micro-environment to the central nervous system, thus it may contain specific biomarkers involved in the pathogenesis of multiple sclerosis (MS).
OBJECTIVES: We aimed to study a large array of inflammatory CSF biomarkers in patients with suspected MS to recognize potential early diagnostic markers.
METHODS: CSF samples were obtained from 115 patients who presented with neurological symptomatology suggestive of MS as follows: clinically isolated syndrome (CIS) = 49, relapsing-remitting multiple sclerosis (RRMS) = 29, and other neurologic disorders (OND) = 37. Protein expression profiles of 30 inflammatory biomarkers were measured by multiplex Luminex bead assay and further analyzed by group comparison statistics, correlation studies and receiver-operating characteristic (ROC) analysis.
RESULTS: Interleukin-12 subunit p40 (IL12p40) demonstrated a significant differential expression pattern between the groups (CIS vs OND: p = 1.17*10(-7); RRMS vs OND: p = 4.98*10(-5)), with higher levels in CIS and RRMS patients. ROC analysis demonstrated excellent diagnostic performance of IL12p40 for discrimination between CIS and OND patients (area under the curve = 0.87 (95% CI 0.78-0.93), p = 0.0001). No associations were found with disease activity or severity measures.
CONCLUSIONS: An increased IL12p40 level characterizes the CSF of MS patients and appears to be helpful in identifying CIS and OND patients early in the process of clinical diagnostic assessment.

Entities:  

Keywords:  Multiple sclerosis; biological markers; cerebrospinal fluid; clinically isolated syndrome; immunology; interleukin-12 subunit p40

Mesh:

Substances:

Year:  2013        PMID: 23722323     DOI: 10.1177/1352458513491166

Source DB:  PubMed          Journal:  Mult Scler        ISSN: 1352-4585            Impact factor:   6.312


  5 in total

Review 1.  [Clinically isolated syndrome].

Authors:  M Platten; T Lanz; M Bendszus; R Diem
Journal:  Nervenarzt       Date:  2013-10       Impact factor: 1.214

Review 2.  Biomarker studies in multiple sclerosis: from proteins to noncoding RNAs.

Authors:  Xiao-Fang Liu; Yue-Bei Luo; Zhao-Hui Luo; Huan Yang
Journal:  Neurochem Res       Date:  2014-07-29       Impact factor: 3.996

3.  Novel Fish Oil-based Bigel System for Controlled Drug Delivery and its Influence on Immunomodulatory Activity of Imiquimod Against Skin Cancer.

Authors:  Khurram Rehman; Mohd Hanif Zulfakar
Journal:  Pharm Res       Date:  2016-09-12       Impact factor: 4.200

Review 4.  Advances in Biomarker-Guided Therapy for Pediatric- and Adult-Onset Neuroinflammatory Disorders: Targeting Chemokines/Cytokines.

Authors:  Michael R Pranzatelli
Journal:  Front Immunol       Date:  2018-04-04       Impact factor: 7.561

5.  Cerebrospinal Fluid and Blood Cytokines as Biomarkers for Multiple Sclerosis: A Systematic Review and Meta-Analysis of 226 Studies With 13,526 Multiple Sclerosis Patients.

Authors:  Zhile Bai; Duanduan Chen; Luyao Wang; Yu Zhao; Tiantian Liu; Yun Yu; Tianyi Yan; Yong Cheng
Journal:  Front Neurosci       Date:  2019-10-04       Impact factor: 4.677

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.